Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Leukemia ; 22(6): 1131-8, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18368071

ABSTRACT

The 190 kD (p190) and 210 kD (p210) Bcr-Abl proteins are responsible for the pathophysiology of Philadelphia chromosome (Ph)(+) leukemia. We applied RNA interference (RNAi) to specific killing of p190(+) cells, and determined the optimal sequences for gene silencing in the BCR, junctional and ABL regions of p190, respectively. Then, p190(+) and p210(+) cells were infected with lentiviral vectors encoding these shRNAs, resulting in efficient killing of p190(+) cells, while p210(+) cells were only sensitive to shBCR and shABL. In p190-transformed Ba/F3 cells, silencing of p190 specifically inhibited tyrosine phospohorylation of Stat5 prior to their death, but did not affect phosphorylation of Jak2, Akt or MEK1/2. In contrast, downregulation of p190 by their treatment with 17-allylamino-17-demetoxygeldanamycin (17-AAG) was associated with reduced protein levels of Jak2, Akt and MEK1/2. shRNA targeting p190 collaborated additively with imatinib and 17-AAG in growth inhibition of Ba/F3-p190wt and imatinib-resistant Ba/F3-p190Y253 H cells. Collectively, RNAi-mediated silencing of p190 is a promising option both for delineating signal transduction and for therapeutic application in 190(+) leukemia.


Subject(s)
Cell Proliferation/drug effects , Fusion Proteins, bcr-abl/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Protein Kinase Inhibitors/pharmacology , Protein-Tyrosine Kinases/antagonists & inhibitors , RNA Interference , STAT5 Transcription Factor/metabolism , Animals , Benzamides , Benzoquinones/pharmacology , Blotting, Western , Cell Survival/drug effects , Cell Survival/physiology , Colony-Forming Units Assay , Fusion Proteins, bcr-abl/metabolism , Hematopoiesis/drug effects , Hematopoiesis/physiology , Imatinib Mesylate , Lactams, Macrocyclic/pharmacology , Lentivirus/genetics , Mice , Piperazines/pharmacology , Precursor Cells, B-Lymphoid/metabolism , Precursor Cells, B-Lymphoid/pathology , Pyrimidines/pharmacology , RNA, Small Interfering/pharmacology , Signal Transduction
2.
Oncogene ; 25(4): 493-502, 2006 Jan 26.
Article in English | MEDLINE | ID: mdl-16158058

ABSTRACT

The retinoblastoma (Rb) gene product is a tumor suppressor that is mutated or inactivated in many types of human cancers. Although Rb is known to be an upstream negative regulator of Abl protein tyrosine kinase, we propose here that Rb also functions as a downstream effector of Abl that plays a positive role in survival of Abl-dependent human tumor cells, including Bcr/Abl-positive chronic myelogenous leukemia (CML). We show that Rb is constitutively phosphorylated at tyrosine in Abl-dependent tumor cells, and that Abl phosphorylates Rb specifically at Y805 within the C-terminal domain of the molecule. We also show that ectopic expression of Rb induces apoptosis in Abl-dependent tumor cells by inhibiting the Abl tyrosine kinase activity, and that Rb-induced apoptosis is compromised by Abl-catalysed phosphorylation of Rb at Y805. Furthermore, the silencing of endogenous Rb by RNA interference induced apoptosis in Abl-dependent tumor cells. Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML.


Subject(s)
Neoplasms/pathology , Proto-Oncogene Proteins c-abl/physiology , Retinoblastoma Protein/physiology , Apoptosis , Catalysis , Cell Survival , HeLa Cells , Humans , Neoplasms/enzymology , Phosphorylation , RNA Interference
3.
Cancer Gene Ther ; 13(4): 385-92, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16244591

ABSTRACT

Glioblastomas are the most common primary brain tumors in adults. These tumors exhibit a high degree of vascularization, and malignant progression from astrocytoma to glioblastoma is often accompanied by increased angiogenesis and the upregulation of vascular endothelial growth factor and its receptors. In this study, we investigated the in vivo antiangiogenic and antitumor effects of brain-specific angiogenesis inhibitor 1 (BAI1) using human glioblastoma cell lines. Glioblastoma cells were transduced with an adenoviral vector encoding BAI1 (AdBAI1), and Northern and Western blot analyses, respectively, demonstrated BAI1 mRNA and protein expression in the transduced tumor cells. Using an in vivo neovascularization assay, we found that angiogenesis surrounding AdBAI1-transduced glioblastoma cells transplanted into transparent skinfold chambers of SCID mice was significantly impaired compared to control treated cells. Additionally, in vivo inoculation with AdBAI1 of established subcutaneous or intracerebral transplanted tumors significantly impaired tumor growth and promoted increased mouse survival. Morphologically, the tumors exhibited signs of impaired angiogenesis, such as extensive necrosis and reduced intratumoral vascular density. Taken together, these data strongly indicate that BAI1 may be an excellent gene therapy candidate for the treatment of brain tumors, especially human glioblastomas.


Subject(s)
Angiogenic Proteins/biosynthesis , Brain Neoplasms/blood supply , Glioblastoma/blood supply , Neovascularization, Pathologic/therapy , Adenoviridae/genetics , Angiogenic Proteins/genetics , Animals , Brain Neoplasms/pathology , Brain Neoplasms/therapy , Cell Line, Tumor , Genetic Therapy , Genetic Vectors , Glioblastoma/pathology , Glioblastoma/therapy , Humans , Mice , Mice, SCID , Neoplasm Transplantation , RNA, Messenger/metabolism , Receptors, G-Protein-Coupled , Transduction, Genetic
4.
Gene Ther ; 10(17): 1446-57, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12900759

ABSTRACT

Difficulty in gene transduction of human blood cells, including hematopoietic stem cells, has hampered the development of gene therapy applications for hematological disorders, encouraging the development and use of new gene delivery systems. In this study, we used a third-generation self-inactivating (SIN) lentiviral vector system based on human immunodeficiency virus type 1 (HIV-1) to improve transduction efficiency and prevent vector-related toxicity. The transduction efficiency of the HIV-1-based vector was compared directly with the Moloney murine leukemia virus (MLV) SIN vector in human leukemia cell lines. Initial transduction efficiencies were almost 100% for the HIV and less than 50% for the MLV vectors. Similar results were observed in 11 types of primary cells obtained from leukemia or myeloma patients. Transgene expression persisted for 8 weeks in cells transduced with the HIV vector, but declined with the MLV vector. In addition, resting peripheral blood lymphocytes and CD34(+) hematopoietic cells were transduced successfully with the HIV vector, but not with the MLV vector. Finally, we confirmed vector gene integration in almost all colony-forming cells transduced with the HIV vector, but not with the MLV vector. In conclusion, this lentiviral vector is an excellent gene transduction system for human blood cells because of its high gene transduction and host chromosome integration efficiency.


Subject(s)
Genetic Therapy/methods , Genetic Vectors/administration & dosage , HIV-1/genetics , Hematologic Diseases/therapy , Hematopoietic Stem Cells/virology , Transduction, Genetic/methods , Cells, Cultured , Gene Expression , Genetic Engineering , Genetic Vectors/genetics , Humans , Leukemia/therapy , Moloney murine leukemia virus/genetics , Multiple Myeloma/therapy , Time Factors , Transgenes , Tumor Cells, Cultured
5.
Vaccine ; 19(20-22): 2995-3003, 2001 Apr 06.
Article in English | MEDLINE | ID: mdl-11282211

ABSTRACT

In order to examine the feasibility of Gag-expression DNA as a potential candidate for HIV vaccine using a mouse model, we injected DNA into mice either intramuscularly or by using a gene gun. Both methods induced a low level of antibody production. However, after booster immunization with p24 protein emulsified with complete Freund's adjuvant via a footpad, we found that only the preceding intramuscular DNA immunization induced an anti-Gag Th1-type (IgG(2a)) antibody response, in addition to the enhancement of a Th2-type (IgG(1)) antibody response. Importantly, when mice were boosted intranasally with p24 and cholera toxin, intramuscular DNA injection was found to enhance both systemic and mucosal Gag-specific immune responses. These results indicate that intramuscular DNA immunization confers the inducibility of memory cells, which circulate around various mucosal tissues. Therefore, intramuscular DNA priming, followed by a mucosal booster immunization, could be considered as a regimen applicable to HIV vaccine.


Subject(s)
AIDS Vaccines/immunology , Gene Products, gag/immunology , Vaccines, DNA/immunology , 3T3 Cells , Animals , COS Cells , Female , Gene Products, gag/genetics , HIV Core Protein p24/immunology , Immunity, Mucosal , Mice , Mice, Inbred BALB C , Plasmids , T-Lymphocytes, Cytotoxic/immunology , Th1 Cells/immunology
6.
Virology ; 278(1): 276-88, 2000 Dec 05.
Article in English | MEDLINE | ID: mdl-11112502

ABSTRACT

More than 10 G protein-coupled receptors (GPCRs) have been reported to act as coreceptors for entry of human and simian immunodeficiency viruses (HIV and SIV). We investigated the utilization of six GPCRs as coreceptors by T-cell-line-adapted HIV-2 strains (CBL-20, CBL-21, CBL-23, GH-1, ROD, and SBL6669) and SIV strains (SIVagmTYO-1, SIVmac251, and SIVmndGB-1). NP-2/CD4 cells were transduced with CCR3, CCR5, CCR8, CXCR4, GPR1, or APJ, and examined for susceptibilities to cell-free HIV/SIV. HIV-2 strains were grouped into two types by their coreceptor usage. The first group, CBL-20 and CBL-21, used CXCR4 exclusively; the other four strains used a few or all of the six coreceptors. These strains could further infect CD4-negative NP-2/CXCR4 or NP-2/CCR5 cells in the presence (all strains) or absence (SBL6669 and ROD strains) of soluble CD4. SIVagm and SIVmnd infected NP-2/CD4/GPR1 cells. The coreceptors CCR3, CCR8, GPR1, and APJ did not mediate the CD4-independent infection. Although HIV-2ROD and SIVmnd infected both NP-2/CD4/CXCR4 and NP-2/CD4/CCR5 cells, only CXCR4 and CCR5, respectively, were used in CD4-independent infection. Binding of virions to CD4-negative cells occurred at 4 degrees C. These findings suggest that there may be a correlation between the promiscuous use of coreceptors by HIV-2/SIV strains and their ability to infect CD4-negative cells.


Subject(s)
CD4 Antigens/physiology , HIV-2/pathogenicity , Receptors, G-Protein-Coupled , Receptors, Virus/physiology , Saccharomyces cerevisiae Proteins , Simian Immunodeficiency Virus/pathogenicity , CD4-Positive T-Lymphocytes/virology , Cell Line , HIV-2/genetics , Humans , Receptors, CCR5/genetics , Receptors, CCR5/physiology , Receptors, CXCR4/genetics , Receptors, CXCR4/physiology , Receptors, Cell Surface/genetics , Receptors, Cell Surface/physiology , Receptors, Chemokine/physiology , Receptors, HIV/physiology , Simian Immunodeficiency Virus/genetics , Transduction, Genetic
7.
Leukemia ; 14(8): 1467-76, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10942244

ABSTRACT

Human T cell leukemia virus type I (HTLV-I) or its transcriptional transactivator, Tax1, was introduced into a human osteosarcoma cell line, HOS, and a Moloney murine sarcoma virus-positive HOS cell line, S+L-HOS. These HTLV-I- or Tax1-expressing cells were injected subcutaneously into nude mice to investigate the effects of HTLV-I on their tumorigenicities. HOS cells did not form any tumors even in the presence of HTLV-I or Tax1. S+L-HOS cells did form small tumors in two-thirds of nude mice. Infection of S+L-HOS cells with HTLV-I, or transduction of Tax1 into S+L-HOS cells markedly facilitated the tumor formation, and the tumor-bearing mice showed marked splenomegaly and neutrophilia. Elevated levels of granulocyte colony-stimulating factor (G-CSF) were detected in sera of these mice and also in the culture supernatants of Tax1-expressing human cells, suggesting that G-CSF in the mouse sera was produced by the human cells. In sera of some mice with splenomegaly and neutrophilia, high levels of murine granulocyte-macrophage colony-stimulating factor (mGM-CSF) were observed, suggesting that Tax1 produced by human cells induced mouse cells to produce mGM-CSF. Only S+L-HOS cell lines expressing Tax1 showed high tumorigenicity in nude mice. Thus, this system will be a useful model of tumor formation, splenomegaly and neutrophilia dependent on Tax1.


Subject(s)
Cell Transplantation , Gene Products, tax/physiology , Human T-lymphotropic virus 1/pathogenicity , Neutrophil Infiltration , Splenomegaly/virology , Animals , Female , Granulocyte Colony-Stimulating Factor/blood , Granulocyte-Macrophage Colony-Stimulating Factor/blood , Hematopoiesis , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , Tumor Cells, Cultured
8.
Cancer Chemother Pharmacol ; 46 Suppl: S73-6, 2000.
Article in English | MEDLINE | ID: mdl-10950152

ABSTRACT

There is no effective treatment for patients with stage IV renal cell cancer (RCC), although the introduction of new therapy is imminent. Cancer gene therapy is currently considered to be one of the most promising therapeutic modalities in the field of cancer treatment. Based on the results of animal studies, vaccination using autologous granulocyte-macrophage colony-stimulating factor-transduced renal cancer cells appears promising. Before initiating a clinical study using an ex vivo gene-transduced autologous cell vaccine-based immunogene therapy for RCC in Japan, in 1992 we initially planned a Japanese version of a clinical protocol in collaboration with a US group. In 1993, the original protocol was refined. We performed five preclinical qualification studies using RCC nephrectomy specimens from patients in 1997, and the results showed that preparation of RCC cells for autologous vaccines at the Clinical Cell Technology Facility, Research Hospital of the Institute of Medical Science, University of Tokyo, was feasible. Subsequently in August 1998, the Ministry of Health and Welfare and the Ministry of Education, Science, Culture, and Sport approved our clinical protocol. We have recruited two patients with stage IV RCC to our study so far. Here we report the background to the initiation of cancer gene therapy in Japan.


Subject(s)
Carcinoma, Renal Cell/therapy , Genetic Therapy/methods , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Kidney Neoplasms/therapy , Adult , Aged , Cancer Vaccines/genetics , Cancer Vaccines/immunology , Cancer Vaccines/therapeutic use , Carcinoma, Renal Cell/immunology , Carcinoma, Renal Cell/pathology , Female , Genetic Vectors , Humans , Kidney Neoplasms/immunology , Kidney Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Retroviridae/genetics , Transduction, Genetic
9.
FEBS Lett ; 473(1): 15-8, 2000 May 04.
Article in English | MEDLINE | ID: mdl-10802050

ABSTRACT

The orphan G protein-coupled receptor APJ has been shown to be a coreceptor for human and simian immunodeficiency virus (HIV and SIV) strains. We have determined that some HIV and SIV strains use APJ as a coreceptor to infect the brain-derived NP-2/CD4 cells. Because apelin is an endogenous ligand for the APJ receptor, we examined the inhibitory effects of apelin peptides on HIV infection, and found that the apelin peptides inhibit the entry of some HIV-1 and HIV-2 into the NP-2/CD4 cells expressing APJ. The inhibitory efficiency has been found to be in the order of apelin-36>apelin-17>apelin-13>apelin-12.


Subject(s)
Carrier Proteins/pharmacology , HIV-1/drug effects , HIV-1/physiology , HIV-2/drug effects , HIV-2/physiology , Peptide Fragments/pharmacology , Receptors, G-Protein-Coupled , Amino Acid Sequence , Apelin , Apelin Receptors , Brain , CD4 Antigens/metabolism , Carrier Proteins/chemistry , Carrier Proteins/metabolism , Chemokines/pharmacology , Giant Cells/metabolism , Giant Cells/pathology , Giant Cells/virology , Glioma/metabolism , Glioma/pathology , Glioma/virology , HIV Reverse Transcriptase/metabolism , HIV-1/enzymology , HIV-1/metabolism , HIV-2/enzymology , HIV-2/metabolism , Humans , Inhibitory Concentration 50 , Intercellular Signaling Peptides and Proteins , Ligands , Molecular Sequence Data , Peptide Fragments/chemical synthesis , Peptide Fragments/chemistry , Peptide Fragments/metabolism , RNA-Directed DNA Polymerase/metabolism , Receptors, CCR5/genetics , Receptors, CCR5/metabolism , Receptors, CXCR4/genetics , Receptors, CXCR4/metabolism , Receptors, Dopamine D2/genetics , Receptors, Dopamine D2/metabolism , Receptors, Virus/genetics , Receptors, Virus/metabolism , Simian Immunodeficiency Virus/enzymology , Simian Immunodeficiency Virus/metabolism , Simian Immunodeficiency Virus/physiology , Tumor Cells, Cultured
10.
Clin Chim Acta ; 296(1-2): 151-61, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10807978

ABSTRACT

We developed a spectrophotometric assay for serum platelet-activating factor acetylhydrolase (PAF-AH, EC 3.1.1.47.) activity using a platelet-activating factor (PAF) analogue with a 4-nitrophenyl group as substrate. PAF-AH hydrolyzes the sn-2 position of the substrate ¿1-myristoyl-2-(p-nitrophenylsuccinyl)phosphatidylcholine, producing p-nitrophenyl succinate. This liberation was spectrophotometrically monitored and the activity determined from the change in absorption. The assay does not require radioisotopes and is applicable to an automatic analyzer. Utilizing this assay with an automatic analyzer, it is possible to measure the activities of thousands of samples in a few hours with excellent precision (CV 0.5%, n=30) and high correlation (r=0.979, n=100) with the results of a conventional radioisotopic assay. The assay should be particularly useful for clinical diagnostics.


Subject(s)
Phospholipases A/blood , Spectrophotometry , 1-Alkyl-2-acetylglycerophosphocholine Esterase , Cholic Acids , Humans , Hydrolysis , Nitrophenols , Platelet Activating Factor/analogs & derivatives , Sensitivity and Specificity , Substrate Specificity
11.
J Virol ; 74(2): 619-26, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10623723

ABSTRACT

More than 10 G protein-coupled receptors (GPCRs) have been shown to act as coreceptors for infection of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIV). We have isolated HIV-1 variants infectious to primary brain-derived CD4-positive cells (BT-3 and BT-20/N) and U87/CD4 glioma cells that are resistant to T-cell line-tropic (T-tropic), macrophage-tropic (M-tropic), and T- and M-tropic (dualtropic) (X4, R5, and R5X4) HIV-1 strains. These primary brain-derived cells were also highly susceptible to HIV-2(ROD), HIV-2(SBL6669), and SIV(mndGB-1). A factor or coreceptor that determines the susceptibility of these brain-derived cells to these HIV and SIV strains has not been fully identified. To identify this coreceptor, we examined amino acid sequences of all known HIV and SIV coreceptors and noticed that tyrosine residues are well conserved in their extracellular amino-terminal domains. By this criterion, we selected 18 GPCRs as candidates of coreceptors for HIV and SIV strains infectious to these brain-derived cells. mRNA expression of an orphan GPCR, RDC1, was detected in the brain-derived cells, the C8166 T-cell line, and peripheral blood lymphocytes, all of which are susceptible to HIV-1 variants, but not in macrophages, which are resistant to them. When a CD4-expressing cell line, NP-2/CD4, which shows strict resistance to infection not only with HIV-1 but also with HIV-2 or SIV, was transduced with the RDC1 gene, the cells became highly susceptible to HIV-2 and SIV(mnd) strains but to neither M- nor T-tropic HIV-1 strains. The cells also acquired a low susceptibility to the HIV-1 variants. These findings indicate that RDC1 is a novel coreceptor for several HIV-1, HIV-2, and SIV strains which infect brain-derived cells.


Subject(s)
HIV-1/metabolism , HIV-2/metabolism , Receptors, Cell Surface/metabolism , Receptors, Chemokine , Receptors, G-Protein-Coupled , Receptors, HIV/metabolism , Receptors, Virus/metabolism , Simian Immunodeficiency Virus/metabolism , Animals , CD4 Antigens/metabolism , Cell Line , Gene Expression , HIV-1/physiology , HIV-2/physiology , Humans , Phylogeny , Receptors, CXCR , Receptors, Cell Surface/classification , Receptors, Cell Surface/genetics , Receptors, HIV/classification , Receptors, HIV/genetics , Receptors, Virus/classification , Receptors, Virus/genetics , Simian Immunodeficiency Virus/physiology , Tumor Cells, Cultured
12.
Virology ; 265(2): 264-73, 1999 Dec 20.
Article in English | MEDLINE | ID: mdl-10600598

ABSTRACT

G protein-coupled receptors serve as coreceptors in the infection process of human immunodeficiency virus type-1 (HIV-1), type-2 (HIV-2), and simian immunodeficiency virus (SIV). In this study, we showed that a CXC-CKR, CXCR5/BLR1, is a novel coreceptor for HIV-2, but for neither HIV-1 nor SIV. The expression of CXCR5 was detected by polymerase chain reaction after reverse transcription of cellular mRNA from S+L-HOS/CD4 cells and MT-2 human T cells, and the CXCR5 gene was cloned into an expression vector. S+L-HOS/CD4 cells were susceptible to several HIV-2 strains but not most HIV-1 strains. To examine a coreceptor activity of CXCR5, we used NP-2/CD4, which is a human glioma cell line, NP-2, transduced with the CD4 gene that shows strict resistance to infection with HIV-1, HIV-2, SIVmac, SIVagm, or SIVmnd strain. When CXCR5 was transduced into NP-2/CD4 cells, they became highly susceptible to HIV-2ROD and HIV-2CBL23 strains in a CD4-dependent manner but to not to HIV-1 or SIV strains. Anti-CXCR5 monoclonal antibody and a ligand for CXCR5, BCA-1, inhibited HIV-2 infection to NP-2/CD4/CXCR5 cells. Our findings suggest a possibility that CXCR5/BLR1 serves as a coreceptor for HIV-2 strains in vivo.


Subject(s)
HIV-2/metabolism , Receptors, Chemokine/metabolism , Receptors, Cytokine/metabolism , Receptors, HIV/metabolism , Animals , Antibodies, Monoclonal/immunology , CD4 Antigens/genetics , CD4 Antigens/metabolism , Cell Line, Transformed , Cloning, Molecular , Flow Cytometry , Gene Expression , Giant Cells , HIV-1/physiology , HIV-2/growth & development , Humans , Ligands , Receptors, CXCR4/genetics , Receptors, CXCR5 , Receptors, Chemokine/genetics , Receptors, Chemokine/immunology , Receptors, Cytokine/genetics , Receptors, Cytokine/immunology , Receptors, HIV/genetics , Receptors, HIV/immunology , Simian Immunodeficiency Virus/physiology , Transfection , Tumor Cells, Cultured
13.
Bioorg Med Chem Lett ; 9(14): 2039-42, 1999 Jul 19.
Article in English | MEDLINE | ID: mdl-10450977

ABSTRACT

A series of polyunsaturated fatty acid anilides were synthesized and evaluated as ACAT inhibitors. Compound 24 had potent inhibitory activity against microsomal ACAT derived from U937, HepG2 and Caco-2 cell lines. Therefore, it might be expected to act as an antiarteriosclerotic and hypocholesterolemic agent. Interestingly, the ACAT inhibitory potency of 24 varied significantly depending on the source of the enzyme.


Subject(s)
Docosahexaenoic Acids/chemical synthesis , Docosahexaenoic Acids/pharmacology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Fatty Acids, Unsaturated/chemical synthesis , Fatty Acids, Unsaturated/pharmacology , Sterol O-Acyltransferase/antagonists & inhibitors , Adrenal Glands/enzymology , Anilides/chemical synthesis , Anilides/pharmacology , Animals , Anticholesteremic Agents/chemical synthesis , Anticholesteremic Agents/pharmacology , Cell Line , Docosahexaenoic Acids/chemistry , Dogs , Drug Evaluation, Preclinical , Eicosapentaenoic Acid/chemistry , Humans , Inhibitory Concentration 50 , Intestines/enzymology , Liver/enzymology , Macrophages/drug effects , Macrophages/enzymology , Microsomes/drug effects , Microsomes/enzymology , Rabbits , Species Specificity
14.
Biochem Biophys Res Commun ; 261(2): 357-63, 1999 Aug 02.
Article in English | MEDLINE | ID: mdl-10425190

ABSTRACT

Heat shock cognate protein 70 (HSC70) has been shown to bind to the peptide corresponding to amino acids 197 to 216 of human T-cell lymphotropic virus type I (HTLV-I) envelope protein, gp46, and an anti-HSC70 monoclonal antibody (mAb) inhibits HTLV-I-induced syncytium formation. These findings suggest that HSC70 is necessary for the entry of HTLV-I into its target cells. Here we showed that HSC70 directly binds to gp46 by co-immunoprecipitation of HSC70 and gp46 from HTLV-I-producing human T-cell lysate. However, transduction of human HSC70 cDNA into BaF3 cells, which were found to be highly resistant to HTLV-I infection, did not support the HTLV-I entry, and HSC70 expressed in NIH3T3 cells, which were found to be almost resistant to syncytium formation upon cocultivation with HTLV-I-producing cells but sensitive to infection with cell-free HTLV-I, enhanced cell fusion induced by HTLV-I-producing cells, but did not enhance the entry of cell-free HTLV-I into these cells. The mAb against HSC70 inhibited syncytium formation in NIH3T3 cells expressing HSC70, but showed little effect on infection of these cells with cell-free HTLV-I. These findings indicate that HSC70 markedly enhances syncytium formation induced by HTLV-I but does not facilitate HTLV-I entry into target cells.


Subject(s)
Carrier Proteins/physiology , Cell Fusion/physiology , HSP70 Heat-Shock Proteins , Human T-lymphotropic virus 1/pathogenicity , 3T3 Cells , Animals , Antibodies, Monoclonal/pharmacology , Base Sequence , Carrier Proteins/genetics , Carrier Proteins/immunology , Cats , Cell Line , DNA Primers/genetics , Gene Products, env/genetics , Gene Products, env/physiology , Giant Cells/pathology , Giant Cells/physiology , HSC70 Heat-Shock Proteins , Human T-lymphotropic virus 1/genetics , Humans , Mice , Rats , Retroviridae Proteins, Oncogenic/genetics , Retroviridae Proteins, Oncogenic/physiology , Transduction, Genetic
15.
Virology ; 259(2): 324-33, 1999 Jul 05.
Article in English | MEDLINE | ID: mdl-10388657

ABSTRACT

We examined the effect of amino acid substitutions of the GPGR (glycine-proline-glycine-arginine) tip sequence at the V3 domain of the Env protein of human immunodeficiency virus type 1 (HIV-1) on its cell tropism and coreceptor use. We changed the GPGR sequence of a T-cell line (T)- and macrophage (M)-tropic (R5-R3-X4) HIV-1 strain, GUN-1wt, to GA(alanine)GR (the resulting mutant was designated GUN-1/A), GL(leucine)GR (GUN-1/L), GP(proline)GR (GUN-1/P), GR(arginine)GR (GUN-1/R), GS(serine)GR (GUN-1/S), or GT(threonine)GR (GUN-1/T). GUN-1/A, GUN-1/S, and GUN-1/T mutants infected brain-derived cells such as a CD4-transduced glioma cell line, U87/CD4, and a brain-derived primary cell strain, BT-20/N, as well as T-cell lines in a CD4-dependent manner, although the plating of these mutants onto macrophages was inhibited. GUN-1/L, GUN-1/P, and GUN-1/R mutants showed both T- and M-tropism, but did not plate onto the brain-derived cells. A CCR3, CCR5, CCR8, or CXCR4 gene was introduced into a CD4-positive glioma cell line, NP-2/CD4, which demonstrated complete resistance to various HIV-1 strains. Not only HIV-1 strains, which were infectious to macrophages, such as GUN-1wt, GUN-1v, GUN-1/L, and GUN-1/P, but also an HIV-1 strain, GUN-1v, which was hardly infectious to macrophages, grew well in NP-2/CD4 cells expressing CCR3 or CCR5. However, the M-tropic GUN-1/R mutant could not efficiently use CCR5 nor CCR3. No point mutants, except GUN-1/L, grew well in NP-2/CD4 cells expressing CCR8. These findings indicate that the cell tropism of HIV-1 to macrophages and brain-derived cells and their use of the coreceptors were markedly, though not always concomitantly, affected by the tip sequence of the V3 domain.


Subject(s)
Brain/virology , HIV Envelope Protein gp120/physiology , HIV-1/physiology , Macrophages/virology , Peptide Fragments/physiology , Receptors, HIV/metabolism , T-Lymphocytes/virology , Brain/cytology , CD4 Antigens/physiology , Cell Line , Cells, Cultured , HIV Antigens/metabolism , HIV Envelope Protein gp120/chemistry , HIV Envelope Protein gp120/genetics , HIV-1/genetics , Humans , Mutagenesis, Site-Directed , Peptide Fragments/chemistry , Peptide Fragments/genetics , Point Mutation , RNA, Messenger/metabolism , RNA, Viral/metabolism , Receptors, HIV/genetics , Reverse Transcriptase Polymerase Chain Reaction , Transfection
16.
Biochem Biophys Res Commun ; 258(2): 313-21, 1999 May 10.
Article in English | MEDLINE | ID: mdl-10329384

ABSTRACT

CD4 and one of the G-protein-coupled receptors (GPCRs) on the cell surface function as a receptor and a coreceptor, respectively, in infection of cells with human and simian immunodeficiency viruses (HIV/SIV). To determine which GPCRs can be coreceptors for HIV (HIV-1 and HIV-2) or SIV infection, several cell lines, including human osteosarcoma HOS-T4 cells and human glioma U87/CD4 cells, have been used. However, these cells often show susceptibilities to some HIV or SIV strains before transduction of GPCRs. The results of this study showed that a CD4-transduced human glioma cell line, NP-2/CD4, a human erythroleukemia cell line, K562/CD4, and a human ovarian cancer cell line, TYK/CD4, were completely resistant to the HIV-1 and HIV-2 strains tested. After transduction of several GPCRs into NP-2/CD4, K562/CD4, or TYK/CD4 cells, NP-2/CD4 cells but not K562/CD4 or TYK/CD4 cells mostly showed expected susceptibilities to several HIV strains. Therefore, an NP-2 cell system would be useful to determine the coreceptor usage of HIV isolates, to find a new coreceptor for HIV/SIV, and to analyze the early stages of HIV/SIV infection.


Subject(s)
CD4 Antigens/metabolism , GTP-Binding Proteins/metabolism , Glioma/metabolism , HIV/metabolism , Receptors, HIV/metabolism , Base Sequence , DNA Primers , Glioma/pathology , Humans , Transduction, Genetic , Tumor Cells, Cultured
17.
J Virol ; 73(6): 5231-9, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10233994

ABSTRACT

Twelve G protein-coupled receptors, including chemokine receptors, act as coreceptors and determinants for the cell tropisms of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIV). We isolated HIV-1 variants from T-cell-line (T)- and macrophage (M)-tropic (i.e., dualtropic) (R5-R3-X4) HIV-1 strains and also produced six HIV-1 mutants carrying single-point amino acid substitutions at the tip of the V3 region of the Env protein of HIV-1. These variants and three mutants infected brain-derived CD4-positive cells that are resistant to M-, T-, or dualtropic (R5, X4, or R5-X4) HIV-1 strains. However, a factor that determines this cell tropism has not been identified. This study shows that primary brain-derived fibroblast-like cell strains, BT-3 and BT-20/N, as well as a CD4-transduced glioma cell line, U87/CD4, which were susceptible to these HIV-1 variants and mutants and the HIV-2ROD strain, expressed mRNA of an orphan G protein-coupled receptor (GPCR), GPR1. When a CD4-positive cell line which was strictly resistant to infection with diverse HIV-1 and HIV-2 strains was transduced with GPR1, the cell line became susceptible to these HIV-1 variants and mutants and to an HIV-2 strain but not to T- or dualtropic HIV-1 strains, and numerous syncytia formed after infection. These results indicate that GPR1 functions as a coreceptor for the HIV-1 variants and mutants and for the HIV-2ROD strain in vitro.


Subject(s)
HIV-1/physiology , HIV-2/physiology , Receptors, Cell Surface/physiology , Receptors, G-Protein-Coupled , Receptors, HIV/physiology , Saccharomyces cerevisiae Proteins , Virus Replication , Brain/virology , Cell Line , Glioma/virology , Humans , Structure-Activity Relationship
18.
Eur Surg Res ; 31(1): 48-56, 1999.
Article in English | MEDLINE | ID: mdl-10072610

ABSTRACT

The present study was designed to elucidate the effectiveness of portal decompression and FK506 (FK) pretreatment in extended hepatectomy in dogs. In the first set of experiment the effect of portal decompression was evaluated in two groups of dogs which underwent extended hepatectomies (80%) with or without (control) a side-to-side portacaval shunt. The presence of the shunt significantly (p < 0.05) improved the 7-day survival of the animals (57.1%) when compared with those of the control group (28.6%) and eventually the portal pressure was significantly lower and mean arterial pressure was significantly higher in the shunt group (p < 0. 05). Moreover, the animals with lower portal pressure (

Subject(s)
Hepatectomy , Liver Regeneration/drug effects , Liver Regeneration/physiology , Portacaval Shunt, Surgical , Tacrolimus/therapeutic use , Animals , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/surgery , Dogs , Female , Humans , Hypertension, Portal/surgery , Liver Neoplasms/drug therapy , Liver Neoplasms/surgery , Male
19.
Surgery ; 125(1): 23-32, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9889794

ABSTRACT

BACKGROUND: Endothelin-1 (ET-1), a novel vasoconstrictor, possibly plays a role in the mediation of ischemia/reperfusion (I/R) injury. Tacrolimus (FK506) and cyclosporin A (CsA) were reported to maintain tissue microcirculation of the liver subjected to I/R. This study investigated the effects of these immunosuppressants on intestinal I/R in terms of intestinal tissue microcirculation associated with ET-1. METHODS AND RESULTS: Male S-D rats were pretreated twice with FK506 (0.2 mg/kg), CsA (10 mg/kg) or only saline solution (0.5 mL). The tissue microcirculation in the control was reduced after I/R (29% +/- 10%) accompanied by hypotension, increased tissue ET-1 expression (25.0% +/- 6.4% to 67.9% +/- 5.0% 60 minutes after reperfusion), and increased ET-1 level in the portal blood (3.4 +/- 0.9 to 23.6 +/- 6.1 pg/mL). FK506 suppressed ET-1 expression (27.3% +/- 5.2%, 4.1 +/- 2.2 pg/mL), maintained microcirculation (96% +/- 16%), and blood pressure, reduced histologic damage, and improved survival. CsA had a similar but weaker effect compared with FK506. An additional experiment was performed with BQ485Na (BQ), an ETA receptor antagonist, to evaluate the genuine role of ET-1. BQ showed almost the same effects as FK506. CONCLUSIONS: FK506 and CsA, particularly the former, maintain microcirculation and protect the tissue from I/R injury by suppressing the production and release of ET-1.


Subject(s)
Cyclosporine/pharmacology , Endothelin-1/biosynthesis , Immunosuppressive Agents/pharmacology , Intestine, Small/blood supply , Intestine, Small/physiology , Ischemia/physiopathology , Microcirculation/physiology , Receptors, Endothelin/physiology , Reperfusion Injury/physiopathology , Tacrolimus/pharmacology , Animals , Azepines/pharmacology , Blood Pressure , Endothelin Receptor Antagonists , Endothelin-1/antagonists & inhibitors , Endothelin-1/blood , Hypotension/physiopathology , Intestine, Small/drug effects , Ischemia/metabolism , Ischemia/pathology , Male , Microcirculation/drug effects , Oligopeptides/pharmacology , Portal System , Rats , Rats, Sprague-Dawley , Receptor, Endothelin A , Reperfusion Injury/metabolism , Reperfusion Injury/pathology , Survival Rate , Time Factors
20.
Hepatology ; 27(6): 1554-62, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9620326

ABSTRACT

As in other tumors, the assessment of microvessel density (MVD) in hepatocellular carcinoma (HCC) may be essential to perform an effective anti-angiogenic therapy for this tumor. The relationship between vascular endothelial growth factor (VEGF) and MVD of HCC as well as the surrounding liver remains to be elucidated. In 71 patients who had undergone curative hepatic resection for HCC, MVD and VEGF expressions were evaluated for HCC and the liver by quantitative reverse-transcription polymerase chain reaction (RT-PCR) and/or immunostaining. The intensity and extent of VEGF immunoreactivity were evaluated using a computer image analyzer-cell analysis system (CAS). Angiographic data were re-evaluated and compared with MVD in 50 tumors. Tumoral MVD was significantly correlated with tumor capsule formation (t test, P = .0016). Small HCCs (< or = 2 cm) had a significantly lower MVD compared with moderate-sized HCCs (2-5 cm) (t test, P = .016), and the MVD of large HCCs was relatively lower than that of moderate tumors. Tumor vascularity on angiography was not correlated with the MVD. Neither VEGF mRNA levels nor protein expression in HCC were correlated with the tumoral MVD or any histopathological features of the tumor. However, cirrhotic livers had significantly higher MVD and VEGF expressions compared with noncirrhotic livers (t test, P = .0015 and P = .047, respectively). Only the MVD of tumor was significantly correlated with intrahepatic recurrence (t test, P = .0048) and disease-free survival (DFS) rates (log rank test, P = .0035). Moreover, the MVD was an independent predictor for DFS by multivariate analysis (chi2 test, P = .03). In conclusion, the MVD in HCC may be involved in the dismal prognosis of this tumor, and VEGF may be associated with the angiogenic process of the cirrhotic liver, but not with the angiogenesis of HCC.


Subject(s)
Carcinoma, Hepatocellular/blood supply , Carcinoma, Hepatocellular/metabolism , Endothelial Growth Factors/physiology , Liver Neoplasms/blood supply , Liver Neoplasms/metabolism , Lymphokines/physiology , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Adult , Aged , Carcinoma, Hepatocellular/pathology , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Female , Humans , Liver Neoplasms/pathology , Male , Middle Aged , Polymerase Chain Reaction , RNA, Messenger/analysis , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...